Effects of treatment with muramyl dipeptide and certain of its analogs on resistance to Listeria monocytogenes in mice.
AUTOR(ES)
Humphres, R C
RESUMO
Studies were carried out to determine whether treatment of mice with the synthetic adjuvant muramyl dipeptide (MDP) afforded any resistance to infection with Listeria monocytogenes. Regardless of the timing, dose, or route of administration, there was no evidence that treatment with either MDP or two of its analogs (des-MDP or MDP-D-D) induced any resistance to listeria infection in BALB/c, CBA/J, or C57BL/6J mice. In contrast, pretreatment with MDP induced marked protection to infection with Streptococcus pneumoniae (type III).
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=551335Documentos Relacionados
- Effects of muramyl dipeptide treatment on resistance to infection with Toxoplasma gondii in mice.
- Stimulation of nonspecific resistance to infection induced by 6-O-acyl muramyl dipeptide analogs in mice.
- Cell-mediated resistance to infection with Listeria monocytogenes in nude mice.
- Effect of pregnancy on resistance to Listeria monocytogenes and Toxoplasma gondii infections in mice.
- Protective effect of muramyl dipeptide analogs against infections of Pseudomonas aeruginosa or Candida albicans in mice.
